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Abstract
Background: Health-related quality of life (HRQoL) should be seen as a tool that provides an overall view of the
general clinical condition of a COPD patient. The aims of this study were to identify variables associated with
HRQoL and whether they continue to have an influence in the medium term, during follow-up.
Methods: Overall, 543 patients with COPD were included in this prospective observational longitudinal study. At all
four visits during a 5-year follow-up, the patients completed the Saint George’s Respiratory Questionnaire (SGRQ),
pulmonary function tests, the 6-min walk test (6MWT), and a physical activity (PA) questionnaire, among others
measurements. Data on hospitalization for COPD exacerbations and comorbidities were retrieved from the personal
electronic clinical record of each patient at every visit.
Results: The best fit to the data of the cohort was obtained with a beta-binomial distribution. The following
variables were related over time to SGRQ components: age, inhaled medication, smoking habit, forced expiratory
volume in one second, handgrip strength, 6MWT distance, body mass index, residual volume, diffusing capacity of
the lung for carbon monoxide, PA (depending on level, 13 to 35% better HRQoL, in activity and impacts
components), and hospitalizations (5 to 45% poorer HRQoL, depending on the component).
Conclusions: Among COPD patients, HRQoL was associated with the same variables throughout the study period
(5-year follow-up), and the variables with the strongest influence were PA and hospitalizations.
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Background
Chronic diseases are already having and will continue to
have not only profound economic, social and individual
consequences but also a major impact on the use of health
resources and design of new care processes. In this sce-
nario, the patient should play a central role [1].
COPD is a paradigmatic chronic condition. Nowadays,
it is understood as a complex heterogeneous multisystem
disease, with varying levels of progression and activity in
different patients [2, 3]. Because of that, it is necessary to
devise tools which evaluate as broadly and comprehen-
sively as possible, the full complexity of the disease.
Health-related quality of life (HRQoL) is commonly
used as a predictor of other outcomes such as mortality
[4, 5] in COPD patients. Nonetheless, HRQoL is consid-
ered an important outcome in itself in many diseases
and this should also be the case in COPD. In fact,
HRQoL is very often assessed in clinical trials but its use
in routine clinical practice and the impact of this use on
practice has not been thoroughly studied. Considering
that HRQoL gives an overall view of the general clinical
condition of a patient, it should be used more frequently
in daily clinical practice in COPD. Further, several vari-
ables have been related to HRQoL in COPD in various
different studies, but these have usually been limited to
cross-sectional analysis of a small number of variables.
The aims of this study were to identify variables asso-
ciated with HRQoL, in a real-life scenario, without any
kind of established intervention, and whether these vari-
ables initially associated with HRQoL continue to have
an influence in the medium-term during follow-up.
Methods
Participants and data collection
Patients were recruited after being treated for COPD in one
of five outpatient respiratory clinics run by the Respiratory
Service of Galdakao Hospital. Patients were consecutively in-
cluded in the study if they had been diagnosed with COPD
for at least 6months and had been stable for 6weeks. Other
inclusion criteria were forced expiratory volume in one sec-
ond (FEV1) post-bronchodilator < 80% of the predicted value
and a FEV1/forced vital capacity ratio < 70%.
Patients were not eligible for the study if they had been
diagnosed with asthma, any other major respiratory dis-
ease or cancer, or psychiatric or neurological problems
that might hinder effective collaboration. The protocol
was approved by the Ethics and Research Committees of
the hospital (030906005). All candidate patients were
given detailed information about the study and all those
included provided written informed consent.
Study protocol
Sociodemographic variables and smoking habits were re-
corded. The level of dyspnoea was established using the
modified Medical Research Council (mMRC) dyspnoea
scale [6]. Comorbidities were identified by reviewing the
patients’ entire electronic medical record and summa-
rized using the Charlson comorbidity index [7]. HRQoL
was assessed using the validated Spanish version of the
Saint George’s Respiratory Questionnaire (SGRQ) [8, 9].
Complete pulmonary function tests included forced
spirometry, bronchodilator testing, and body plethys-
mography, as well as measurements of diffusing capacity
of the lung for carbon monoxide (adjusted for
hemoglobin) and respiratory muscle strength. These
tests were performed in accordance with the standards
of the Spanish Society of Respiratory Medicine and
Thoracic Surgery (SEPAR) [10]. For theoretical values,
we considered those of the European Community for
Steel and Coal [11].
Physical activity (PA) was measured using a validated
questionnaire [12, 13]. Two 6-min walk tests (6MWTs)
were performed according to American Thoracic Society
guidelines [14]. Peripheral muscle strength was evaluated
in terms of handgrip strength [15].
Follow-up
Patients were followed up for 5 years. At baseline, inter-
views were conducted and the aforementioned measure-
ments were performed in all patients; the interview and
assessments were then repeated in the first, second, and
fifth year of the study period in survivors. No interven-
tions were performed related to this study, and the re-
search team did not take part in patients’ routine care or
the treatment of any exacerbations.
Patient medical records and the hospital database on
hospitalizations were reviewed at each assessment during
this 5-year follow-up period. Vital status was established
by reviewing medical records, the hospital database and
public death registries. Deaths were considered con-
firmed if the name, sex, and date of birth on the record
matched those of the participant.
Statistical analysis
The study sample was described using means and stand-
ard deviations (SD) for continuous variables and fre-
quencies and percentages for categorical variables.
The beta-binomial (BB) distribution was fitted to the
HRQoL scores [16, 17]. The fitting required transform-
ing the original scores to a binomial form as described
thoroughly in the literature [18]. The transformation
was performed based on a minimum clinically important
difference. Jones showed that the estimate for the SGRQ
threshold is consistently around 4 units, regardless of the
method of estimation and the number of the individuals
contributing to the estimate [19]. We developed a trans-
formation process based on the idea that a 4-point
change in the SGRQ scores could be considered
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clinically significant, and hence, we divided the 0 to 100
scale into 4-point length subintervals linking the value of
each score to the value of its subinterval [19, 20]. As a
result of the transformation process, scores were pre-
sented as ordinal scores ranging from 0 to 24. The distri-
bution of the SGRQ scores is shown graphically using
histograms.
The annual change in SGRQ scores was estimated
using a BB mixed-effects model [21]. One independent
model was fitted for each SGRQ component. In this
framework, the coefficients estimated using the BB re-
gression model, in particular, the mixed-effects model,
are interpreted using odd ratios, equivalent to a logistic
regression model, as the probability modelled is that of
experiencing a clinically significant change in 1 year in
the corresponding SGRQ score. All the measurements
were included in the model (one to four for each pa-
tient). Covariates included in the multivariate modelling
process as fixed effects were: time, sex, age, smoking
habit, body mass index, FEV1, residual volume (RV), dif-
fusing capacity of the lung for carbon monoxide
(DLCO), 6MWT distance, PA, Charlson comorbidity
index, handgrip strength, hospitalizations during the
previous year and treatment; while patient was included
as a random effect. Finally, only significant covariates
were retained in the multivariate models. MacFadden’s
rho-squared was calculated for each final model and it
was interpreted as the percentage of variability in SGRQ
scores that was explained by the model [22]. The im-
portance of each covariate in the models was measured
using standardized estimates of the beta coefficients in
the model and presented graphically along with the 95%
confidence intervals.
Factors related to a clinically significant impairment in
HRQoL (4 points in the SGRQ components) over a 1-year
period were also studied. The annual change in SGRQ
scores was calculated from baseline to 1 year and from 1
to 2 years. Generalized linear mixed models with a logistic
link function were used to estimate the probability of an
at least 4-point increase in SGRQ score, independently for
each component. All the aforementioned covariates were
entered into the models.
Results
The cohort included 543 patients, the majority of whom
were men (96%) with moderate obstruction. Other char-
acteristics of the cohort including HRQoL at the baseline
and during the follow-up are summarised in Table 1.
Figure 1 shows the distribution of the HRQoL scores
at baseline for the three components of the SGRQ. The
left side of the Fig. (a) shows the original scores observed
and their fit to the normal distribution, and the right
side of the Fig. (b) the transformed scores and their fit
to the BB distribution. The fit of the BB distribution to
the transformed scores was better than that of the nor-
mal distribution to the original scores for all the compo-
nents, especially at the two extremes of the scale.
Results of the multivariate BB mixed-effects model, ad-
justed for covariates, are presented in Tables 2, 3, and 4
and Fig. 2 for each of the SGRQ components. The asso-
ciation found remained stable from the measurements
taken at the beginning of the study to those taken during
the 5-year follow-up in COPD patients that remained
alive. PA and hospitalization for COPD exacerbation
were the variables most strongly associated with HRQoL
in all three components of the SGRQ. Specifically, PA
was related to a 13 to 35% better activity and impacts
scores of HRQoL, depending on the level of PA, whereas
hospitalizations were related to 5 to 45% poorer HRQoL
scores, across all three components, depending on the
number of hospitalizations.
Pulmonary function was associated with all HRQoL
components, with an approximately 5% improvement in
HRQoL score for each 100ml increase in FEV1 and 11%
increase in DLCO. These results were of a similar mag-
nitude to the improvement seen with each 5-kg increase
in handgrip strength and 25-m increase in the 6MWT.
A bigger deterioration of HRQoL was caused by every
9% increase in RV, but its level of influence was lower
than that of FEV1 or DLCO.
Age showed a positive relationship with HRQoL in all
the components of the SGRQ.
The amount of random variance in the SGRQ scores
explained by the model ranged from 24% for symptoms
to 44% for activity and impacts. The probability of clinic-
ally significant impairment in 1 year was estimated to be
0.33 for the impacts component and 0.36 for the activity
component, and it did not depend on any of the covari-
ates. On the other hand, the probability of clinically
significant impairment in 1 year for the symptoms com-
ponent depended only on the presence of cardiovascular
disease (CVD) and was estimated to be 0.44 for patients
without CVD; while the OR for patients with CVD com-
pared to those without CVD was 1.41 (95% CI (1.05–
1.90).
Discussion
1. Important variables in characterization and
prognosis in COPD (PA, hospitalizations, exercise
capacity, muscular strength, FEV1, DLCO, smoking
habit, and age) were associated with HRQoL from
the beginning to the end of the 5-year follow-up.
2. The HRQoL was well fit by the BB distribution,
justifying the use of BB regression for the analysis
instead of traditional normal distribution and linear
models usually used in this kind of study.
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n = 480 (88%)
2-years
n = 428 (79%)
5-year
n = 324 (60%)
SGRQ Symptoms 44.5 (22.2) 42.5 (22.4) 43.1 (23.5) 44.1 (23.4)
Activity 48.7 (24.9) 45.9 (25.0) 46.6 (25.0) 47.4 (25.4)
Impacts 32.0 (20.9) 30.4 (21.1) 30.1 (20.4) 30.4 (20.9)
Sex M 522 (96.1) 459 (95.6) 408 (95.3) 308 (95.1)
F 21 (3.9) 21 (4.4) 20 (4.7) 16 (4.9)
Age Years 68.3 (8.3) 67.6 (8.4) 67.4 (8.3) 66.2 (8.4)
BMI 28.3 (4.4) 28.3 (5.2) 28.1 (4.4) 27.6 (4.8)
Dyspnea (mMRC) 0 69 (12.7) 85 (17.7) 75 (17.5) 57 (17.6)
1 264 (48.6) 248 (51.7) 188 (43.9) 134 (41.4)
2 166 (30.6) 127 (26.5) 142 (33.2) 100 (30.9)
3–4 44 (8.1) 20 (4.3) 23 (5.4) 33 (10.2)
FEV1 ml 1465(441) 1470(501) 1513(470) 1391(451)
FEV1% Percentage 55.0 (13.3) 55.2 (16.0) 57.2 (14.7) 54.3 (14.8)
< 30 18 (3.3) 22 (4.6) 13 (3.0) 14 (4.3)
30–50 167 (30.8) 131 (27.3) 111 (25.9) 118 (36.4)
≥50 358 (65.9) 327 (68.1) 304 (71.0) 192 (59.3)
RV% Percentage 159 (46.9) 158 (47.7) 158 (50.4) 161 (48.4)
DLCO% Percentage 71.5 (23.5) 75.6 (26.6) 76.7 (26.9) 68.1 (21.9)
Smoking habit/status Pack/year 46.8(27.3) 46.3(26.4) 46.5(26.0) 46.8(25.9)
Smoker 114 (23.0) 91 (19.0) 79 (18.5) 58 (17.9)
Former smoker 414 (76.2) 375 (78.1) 338 (79.0) 256 (79.0)
Non smoker 15 (2.8) 14 (2.9) 11 (2.6) 10 (3.1)
6mWT Meters 409 (92) 421 (118) 412 (116) 397 (123)
PA < 2 h/week 48 (8.8) 44 (9.2) 48 (11.2) 62 (19.1)
2–4 h/week 110 (20.3) 103 (21.5) 94 (22.0) 60 (18.5)
> 4 h/weeka 219 (40.3) 203 (42.3) 165 (38.6) 117 (36.1)
Work/intense 166 (30.6) 130 (27.1) 121 (28.3) 85 (26.2)
CCI Points 2.41(1.42) 2.46(1.42) 2.47(1.41) 2.55(1.35)
< 2 172 (31.7) 145 (30.2) 130 (30.4) 87 (26.9)
2–3 264 (48.6) 233 (48.5) 208 (48.6) 159 (48.8)
> 3 107 (19.7) 102 (21.3) 90 (21.0) 79 (24.4)
Strength Handgrip (kg) 34.1 (9.4) 33.7(10.2) 33.0 (9.6) 32.9(10.4)
Previous hospitalizations 0 427 (78.6) 406 (84.6) 377 (88.1) 234 (72.2)
1 80 (14.7) 51 (10.6) 30 (7.0) 40 (12.4)
2 16 (3.0) 14 (2.9) 16 (3.7) 23 (7.1)
3 9 (1.7) 6 (1.3) 4 (0.9) 14 (4.3)
> 3 11 (2.0) 3 (0.6) 1 (0.2) 13 (4.0)
Treatment b 0–1 73 (13.4) 57 (11.9) 48 (11.2) 36 (11.1)
2 121 (22.2) 91 (19.0) 87 (20.3) 56 (17.3)
3 349 (64.3) 330 (68.8) 293 (68.5) 232 (71.6)
Frequencies and percentages by category for categorical variables, and mean and standard deviation for continuous variables are shown
BMI body mass index, CCI Charlson comorbidity index, DLCO carbon monoxide diffusing capacity, Dyspnea mMRC Medical research council scale, FEV1 forced
expiratory volume in the first second, PA physical activity, RV residual volume, 6mWT 6-min walking test
a Gardening subjects were included in this category
b Treatment has been classified as follows: 0–1 out of LABA/LAMA; 2 out of LABA/LAMA/ICS; 3 of them LABA+LAMA+ICS
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3. PA and hospitalizations were the factors with the
strongest influence on HRQoL.
Many studies have identified various different factors as-
sociated with HRQoL in COPD patients; however, what
has not been thoroughly studied is whether or not these
factors maintain their influence over time. Moreover,
these previous cross-sectional studies tend to have only
assessed HRQoL at the start of the study and take it for
granted that the data were normally distributed. In our
study, we carried out four assessments of HRQoL during
the 5 years of follow-up, all of which were included in the
analysis and the BB distribution was applied to the data as
a whole. Previous research found the BB regression ap-
proach to perform better for analysing HRQoL data than
the standard regression approaches based on the normal
distribution of the outcome [16]. Further, in this particular
case, we have shown that the empirical distribution of the
SGRQ scores (Fig. 1) is much better fitted by the BB than
the normal distribution. Moreover, the easy interpretation
of the results in terms of OR is an added advantage of the
BB regression compared to the classical linear regression
approach. Extension of the BB regression model to the BB
mixed-effects model, recently proposed in the literature
[21], allowed us to use all the repeated measurements over
time to estimate the effect of relevant covariates on
Fig. 1 Distribution of the three components of the SGRQ questionnaire at baseline: In the original scale [0, 100] and their fit to the normal
distribution (left); and recoded to an ordinal scale from 0 to 25 and their fit to the beta-binomial distribution (right)
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HRQoL. Considering that not only HRQoL was measured
over time, but also that many covariates were time
dependent, effective statistical analysis should include all
the repeated measurements, considering the longitudinal
design. Thanks to the BB mixed-effects approach, 543 pa-
tients have been analysed based on 1775 correlated re-
cords, providing robustness to the results.
Although the amount of random variance in the
SGRQ scores explained by the models seems low (0.24–
0.44), it should be noted that values of rho-squared tend
to be considerably lower than those of the traditional R-
squared in linear regression. In fact, McFadden [23]
stated that values of 0.2 to 0.4 for rho-squared represent
an excellent fit.
General speaking, PA was the factor with the strongest
positive influence on HRQoL in our cohort. Changes in
PA measured by questionnaires or by accelerometers
have previously been shown to be related to changes in
HRQoL [24, 25]. In our study, we found that it was the
most important factor related to HRQoL during the
whole follow-up and especially for the activity and im-
pacts components of the SGRQ. Previously, our group
had shown that there was an association between
changes in PA and changes in HRQoL. Our current
finding is complementary to those results [24], in that
PA appears as a predictor of HRQoL throughout the
natural history of the disease, regardless of its duration
and severity.
The other variable with a major influence was the oc-
currence of hospitalizations. In this case, it was the
factor with the most strongly growing negative influence
in HRQoL from the first admission. An independent as-
sociation between number of hospitalizations and
HRQoL was previously shown by our group [26], in
agreement with other authors [27]. In the current study,
the relevance of hospitalizations in HRQoL is put into
perspective compared with other variables.
Previous research has found a relationship between
the number of exacerbations and HRQoL measured
by SGRQ [28], but in this study, only 16% were se-
vere exacerbations, and it was the patients with a
high frequency of exacerbation (between 3 and 8/
year) who had a clinically and statistically significantly
poorer HRQoL [28]. Further, the current study adds
weight to the known crucial importance of severe ex-
acerbation in HRQoL [29], and the resulting need to
make prevention of severe exacerbation a priority tar-
get in COPD patients. On the other hand, the rela-
tionship between PA and hospitalization is well
known [12, 30, 31] and our study helps to close the
loop on the relationship between PA, hospitalizations
and HRQoL.
It has been known for several years that FEV1 is re-
lated to HRQoL, especially as severity increases, FEV1
50% being indicated as a turning point associated
with marked impairment of HRQoL [32]. In our study
DLCO had a positive relationship with all the do-
mains of SGRQ, but this influence was lower than that
of FEV1%, as has been published [33]. On the other hand,
other variables such as the body mass index, obstruction,
Table 2 Result of the multiple beta-binomial mixed-effects model adjusted by time-dependent covariates for the Symptoms
component of the SGRQ questionnaire over time
SGRQ β SD(β) P OR 95%CI
Symptoms Intercept 2.79 0.269 < 0.001 – –
Time (year) − 0.005 0.010 0.341 0.991 (0.971–1.010)
Age (5 years) −0.138 0.013 < 0.001 0.871 (0.850–0.893)
FEV1 (100 ml) −0.027 0.005 < 0.001 0.973 (0.964–0.983)
RV% (9%) 0.010 0.004 0.008 1.010 (1.003–1.017)
DLCO% (11%) −0.020 0.009 0.028 0.981 (0.964–0.998)
Handgrip (5 kg) −0.041 0.011 0.001 0.960 (0.939–0.981)
6mWT (25 m) − 0.032 0.005 < 0.001 0.968 (0.958–0.978)
PA None/Any – – – – –
Work/intense −0.198 0.044 < 0.001 0.820 (0.753–0.893)
Previous hospitalizations 0 – – – – –
1 0.197 0.050 < 0.001 1.217 (1.105–1.342)
2 0.284 0.074 < 0.001 1.328 (1.148–1.537)
> 2 0.203 0.068 0.003 1.224 (1.073–1.398)
Sigmaa 0.742 0.024 – – –
DLCO carbon monoxide diffusing capacity, FEV1 forced expiratory volume in the first second, PA physical activity, RV residual volume, 6mWT 6-min walking test,
SD standard deviation, OR odds ratio, CI Confidence interval
a Standard deviation of the random intercept
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dyspnoea and exercise index (BODE index) showed
better correlation with HRQoL (SGRQ) than FEV1
alone [34]. In our study, some of the variables in-
cluded in the BODE index were also related to
HRQoL, but they did not have as strong an influence
as that of PA or hospitalizations. It is worth mention-
ing that muscular strength (handgrip) had a positive
influence on all the components of the SGRQ, as has
been pointed out previously [35].
We want to emphasize that all the variables found to
be associated with HRQoL have remained the same
throughout the follow-up years. Ferrari et al. studied 95
COPD patients that remained alive in a 3-year follow-up
study and found that the variables related to HRQoL
were BODE index and, in particular, dyspnoea at the
start of the study, but BODE index and age 3 years later.
When the components of the BODE index were consid-
ered, the predictors of HRQoL were dyspnoea at base-
line, and dyspnoea, FEV1 and exacerbations (moderate
or severe) at 3 years [36]. This contrasts with our obser-
vation that the variables involved as predictors of
HRQoL did not change throughout the 5-year follow-up.
The small number of patients they included in their
study may have influenced their results.
In our study, age was related to HRQoL. In fact, older
people had better HRQoL after controlling for several
other variables. These results are in agreement with
those of another cohort [37], and while some authors
found opposite results [38], they made no mention of
controlling for confounders. The reasons why HRQoL
Table 3 Result of the multiple beta-binomial mixed-effects model adjusted by time-dependent covariates for the Activity
component of the SGRQ questionnaire over time
SGRQ β SD(β) P OR 95%CI
Activity Intercept 3.998 0.248 < 0.001 – –
Time (years) −0.027 0.009 0.002 0.973 (0.956–0.990)
Age (5 years) −0.140 0.012 < 0.001 0.869 (0.850–0.889)
FEV1 (100 ml) −0.040 0.005 < 0.001 0.961 (0.952–0.970)
RV% (9%) 0.011 0.003 < 0.001 1.011 (1.004–1.017)
DLCO% (11%) −0.057 0.009 < 0.001 0.944 (0.929–0.961)
Handgrip (5 kg) −0.065 0.010 < 0.001 0.937 (0.919–0.955)
6mWT (25 m) − 0.065 0.005 < 0.001 0.937 (0.927–0.947)
Smoking (10 pack/y) 0.024 0.006 < 0.001 1.024 (1.013–1.036)
BMI < 25 – – – – –
25–30 0.153 0.042 < 0.001 1.165 (1.073–1.265)
> 30 0.158 0.047 < 0.001 1.171 (1.068–1.285)
PA < 2 h/week – – – – –
2–4 h/week −0.280 0.062 < 0.001 0.755 (0.669–0.854)
> 4 h/weeka −0.363 0.061 < 0.001 0.696 (0.618–0.784)
Work/intense −0.558 0.068 < 0.001 0.572 (0.501–0.654)
CCI 0–1 – – – – –
> 1 0.096 0.036 0.007 1.101 (1.026–1.180)
Treatmentb 0–1 out of LABA/LAMA – – – – –
2 out of LABA/LAMA/ICS 0.177 0.059 0.003 1.193 (1.062–1.340)
LABA+LAMA+ICS 0.136 0.051 0.008 1.146 (1.036–1.267)
Previous hospitalizations 0 – – – – –
1 0.102 0.043 0.021 1.108 (1.016–1.208)
2 0.299 0.066 < 0.001 1.348 (1.184–1.535)
3 0.281 0.098 0.004 1.325 (1.094–1.604)
> 3 0.307 0.079 < 0.001 1.360 (1.165–1.587)
Sigmac 0.945 0.030 – – –
BMI body mass index, CCI Charlson comorbidity index, DLCO carbon monoxide diffusing capacity, FEV1 forced expiratory volume in the first second, PA physical
activity, RV residual volume, 6mWT 6-min walking test, SD standard deviation, OR odds ratio, CI Confidence interval
a Gardening subjects were included in this category
b Treatment has been classified as follows: 0–1 out of LABA/LAMA; 2 out of LABA/LAMA/ICS; 3 of them LABA+LAMA+ICS
c Standard deviation of the random intercept
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improves as age increases have not been clearly identi-
fied. In our opinion, it is probably a matter of people’s
expectations changing as they get older and/or they pro-
gressively get used to living with the disease.
It might be expected that cardiovascular comorbidities
would play an important role in HRQoL of COPD pa-
tients [39], but this does not seem to be observed, unlike
for other comorbidities, such as depression, which have
been shown to contribute strongly to HRQoL [40]. In a
European cross-sectional study, a cut-off of three comor-
bidities established significant differences in HRQoL,
and though COPD patients with cardiovascular comor-
bidities had worse scores in HRQoL (SGRQ), the min-
imal clinically important difference was not reached
[41]. In our study, comorbidities seem not to have
influenced the HRQoL of the cohort. This could be ex-
plained by the SGRQ, a specific questionnaire, not being
able to capture the whole impact of comorbidities in
these patients. It is plausible that generic questionnaires
are the best instruments to capture the influence of
comorbidities on the HRQoL of COPD patients [42,
43]. For this reason, some authors have suggested
that a combination of generic and specific question-
naires best reflect the impact of comorbidities [42].
This is an issue that should be considered in daily
clinical practice.
Since the study was an observational study, we did not
establish whether the inhaled treatment of patients
matched that recommended in guidelines, and hence,
our results reflect that using more than two inhaled
Table 4 Result of the multiple beta-binomial mixed-effects model adjusted by time-dependent covariates for the Impacts
component of the SGRQ questionnaire over time
SGRQ β SD(β) P OR 95%CI
Impacts Intercept 3.150 0.229 < 0.001 – –
Time (year) −0.026 0.008 0.002 0.974 (0.959–0.991)
Age (5 years) − 0.167 0.010 < 0.001 0.846 (0.829–0.864)
FEV1 (100 ml) −0.031 0.004 < 0.001 0.970 (0.962–0.978)
RV% (9%) 0.013 0.003 < 0.001 1.013 (1.007–1.019)
DLCO% (11%) −0.043 0.008 < 0.001 0.958 (0.943–0.973)
Handgrip (5 kg) −0.057 0.009 < 0.001 0.945 (0.928–0.962)
6mWT (25 m) − 0.053 0.005 < 0.001 0.949 (0.940–0.958)
Smoking (10 pack/y) 0.015 0.006 0.006 1.015 (1.004–1.026)
BMI ≤ 30 – – – – –
> 30 0.129 0.032 < 0.001 1.138 (1.068–1.212)
PA < 2 h/week – – – – –
2–4 h/week −0.101 0.053 0.056 0.904 (0.814–1.002)
> 4 h/weeka −0.256 0.052 < 0.001 0.774 (0.700–0.857)
Work/intense −0.433 0.061 < 0.001 0.649 (0.576–0.731)
CCI 0–3 – – – – –
> 3 −0.120 0.037 0.001 0.887 (0.825–0.953)
Treatmentb 0–1 out of LABA/LAMA – – – – –
2 out of LABA/LAMA/ICS 0.141 0.058 0.014 1.152 (1.028–1.290)
LABA+LAMA+ICS 0.087 0.050 0.084 1.090 (0.988–1.203)
Previous hospitalizations 0 – – – – –
1 0.043 0.041 0.294 1.044 (0.964–1.131)
2 0.257 0.060 < 0.001 1.293 (1.149–1.454)
> 2 0.156 0.054 0.004 1.169 (1.050–1.300)
Sigmac 0.951 0.030 – – –
BMI body mass index, CCI Charlson comorbidity index, DLCO carbon monoxide diffusing capacity, FEV1 forced expiratory volume in the first second, PA physical
activity, RV residual volume, 6mWT 6-min walking test, SD standard deviation, OR odds ratio, CI Confidence interval
a Gardening subjects were included in this category
b Treatment has been classified as follows: 0–1 out of LABA/LAMA; 2 out of LABA/LAMA/ICS; 3 of them LABA+LAMA+ICS
c Standard deviation of the random intercept
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medications was associated with a better quality of life.
Further, a limitation of the study is that our findings are
obtained from a predominantly male cohort and hence
might not fully apply to women. We included several
variables with a recognized impact on COPD patients,
but there are bound to be other variables that also have
an influence. On the other hand, having explored how
the SGRQ works and what we can expect from this kind
of instrument, it is clear that use of this questionnaire is
not feasible in clinical practice, and hence, there is a
need to assess the properties over time of other ques-
tionnaires used in clinical practice (e.g., the COPD As-
sessment Test, and the Clinical COPD Questionnaire) to
confirm whether their behaviour is similar to that dem-
onstrated for SGRQ in this study. Lastly, survival bias
could have minimized the influence of the variables on
the final results of the study. Strengths of the study in-
clude that we have studied a range of variables and how
they maintain their influence on HRQoL, regardless of
disease duration.
Conclusions
HRQoL summarized the general clinical condition of
COPD patients, mirroring the influence of many import-
ant related variables and the same set of variables contin-
ued to have an influence over time. Two key modifiable
factors that influenced HRQoL were PA and hospitaliza-
tions for exacerbation. Further, it is worth investigating a
different methodological approach to HRQoL based on
the BB.
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